KNE Kane Biotech Inc

Kane Biotech Inc. (TSX VENTURE:KNE), is very pleased to report that there is a
strong rate of support and adoption from veterinarians for the recently
announced marketing field test for StrixNB in Manitoba. Many veterinarians are
now recommending StrixNB to their clients as an important part of a regular pet
oral care program. Kane Biotech is a biotechnology company engaged in the
development and commercialization of products that prevent and remove microbial
biofilms. On January 31, 2013 the company announced that it launched its
marketing field test for StrixNB, its revolutionary new pet oral care product in
Manitoba in conjunction with Pet Dental Health Month.


The response to the marketing field test has been very positive with 84% of the
veterinary clinics in Manitoba signing up for the Company's promotional campaign
that coincides with February's Pet Oral Care month. In addition, in the first
two weeks, 48% of these clinics have already placed orders to regularly carry
StrixNB in their clinics. Commercial manufacturing was successfully completed to
supply demand for further expansion across Canada. Accounting and financial
procedures are in place from purchasing raw materials to inventory management to
account collecting from distribution. In addition Standard Operating Procedures
(SOP's) have been developed and are in place for manufacturing and operations
and quality control procedures have been implemented. 


With very encouraging acceptance from both veterinarians and consumers the
Company is now in the process of developing additional product applications such
as toothpastes and dental chews. 


About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and
commercialization of products that prevent and remove biofilms. Biofilms develop
when bacteria and other microorganisms form a protective matrix that acts as a
shield against attack. When in a biofilm, bacteria become highly resistant to
antibiotics, biocides, disinfectants, high temperatures and host immune
responses. This resiliency contributes to human health problems such as
recurrent urinary tract infections, medical device associated infections and
tooth decay. 


Kane Biotech uses patent protected technologies based on molecular mechanisms of
biofilm formation/dispersal and methods for finding compounds that inhibit or
disrupt biofilms. The Company has evidence that these technologies have
potential to significantly improve the ability to prevent and/or destroy
biofilms in several medical and industrial applications. 


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Kane's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Kane's filings with Canadian securities regulatory authorities,
as well as Kane's ability to anticipate and manage the risks associated with the
foregoing. Kane cautions that the foregoing list of important factors that may
affect future results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and others should
carefully consider the foregoing factors and other uncertainties and potential
events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Kane cannot
provide assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update or revise
any forward-looking statement.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Kane Biotech Inc.
Gord Froehlich
President & Chief Executive Officer
204-477-7592
204-453-1314 (FAX)
ir@kanebiotech.com
www.kanebiotech.com


Pure Advertising and Marketing Inc.
Kam Thindal
604-488-9875
kam@puread.ca

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024